US breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.7% during the forecast period. The factors that enable the growth of the market include the prevalence of breast cancer and the initiative by the government and private organizations. Breast cancer is the most commonly diagnosed cancer type in the US. According to the American Cancer society, it is estimated that about 30% of newly diagnosed cancers in women are breast cancer in 2017. About 266,120 new cases of invasive breast cancer and about 63,960 cases of non-invasive breast cancer estimated in 2018 by the American Cancer Society. About 40,920 women died from breast cancer in 2018. The awareness program by the government and research funding also plays an important role in the growth of the breast cancer market in the US. The organization that is contributing to the breast cancer research funding and awareness program includes American Cancer Organization, National Cancer Institute (NCI), Susan G. Komen and others. American cancer provides 162 research grants for breast cancer and funded about $91 million for research in breast cancer.
US breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/Computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.
To Request a Sample of our Report on US Breast Cancer Diagnostics And Therapeutics Market: https://www.omrglobal.com/request-sample/us-breast-cancer-diagnostics-therapeutics-market
US Breast Cancer Diagnostics And Therapeutics Market Segmentation
By Cancer type
- Ductal Carcinoma In-Situ (DCIS)
- Invasive Ductal Carcinoma (IDC)
- Triple Negative Breast Cancer (TNBC)
- Inflammatory Breast Cancer
- Others (Invasive lobular carcinoma)
By Diagnostics
- Mammography
- Biopsy
- PET/CET
- Ultrasound
- Others (MRI)
By Therapeutics
- Chemotherapy
- Hormone Therapy
- Targeted Therapy
- Others (Radiation Therapy, Surgery)
A full Report of US Breast Cancer Diagnostics And Therapeutics Market is Available @ https://www.omrglobal.com/industry-reports/us-breast-cancer-diagnostics-therapeutics-market
Company Profiles
- AbbVie Inc.
- Astellas Pharma Inc.
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Hologic Inc.
- Halozyme, Inc
- Johnson & Johnson Services Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Siemens Healthcare GmbH
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
